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Abstract
The use of a novel inducible FGF signalling system in the frog Xenopus laevis is reported. We show that the lipophilic, synthetic,
dimerizing agent AP20187 is able to rapidly activate signalling through an ectopically expressed mutant form of FGFR1 (iFGFR1) in
Xenopus embryos. iFGFR1 lacks an extracellular ligand binding domain and contains an AP20187 binding domain fused to the intracellular
domain of mouse FGFR1. Induction of signalling by AP20187 is possible until at least early neurula stages, and we demonstrate that
ectopically expressed iFGFR1 protein persists until late neurula stages. We show that activation of signalling through iFGFR1 can mimic
a number of previously reported FGF activities, including mesoderm induction, repression of anterior development, and neural posterior-
ization. We show that competence to morphological posteriorization of the anteroposterior axis by FGF signalling only extends until about
stage 10.5. We demonstrate that the competence of neural tissue to express the posterior markers Hoxa7 and Xcad3, in response to FGF
signalling, is lost by the end of gastrula stages. We also show that activation of FGF signalling stimulates morphogenetic movements in
neural tissue until at least the end of the gastrula stage.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
In recent years, the amphibian embryo has proven to be
an excellent system for studying the role of signalling path-
ways in early development (Dale and Jones, 1999; Hill,
2001; Isaacs, 1997; Moon, 1993; Niehrs, 1999; Smith,
1995). Synthetic mRNA coding for a protein of interest can
readily be injected into early embryos, and its biological
activity can be determined by using the wide range of
functional assays available in frogs. Such approaches have
not only revealed a detailed picture of the role of known
signalling pathways in early patterning and specification,
but have also led to the identification of a wide range of
novel signalling molecules (Bouwmeester et al., 1996; Hsu
et al., 1998; Smith and Harland, 1992). However, a partic-
ular signalling pathway may be involved in a number of
separate processes at different times during development.
The standard approach of mRNA overexpression suffers
from the problem that injected mRNAs are translated from
the time of injection. The initial effects on the development
of the embryo that result from interfering with a particular
pathway may mask any effects that result from interfering
with the pathway during later development. In this way,
mRNA overexpression experiments only give accurate in-
formation regarding the first role of a signalling pathway
during development. It is a common problem in the study of
vertebrate developmental biology: how to produce timed
inhibition or activation of a given signalling pathway?
For downstream effectors of many signalling pathways
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(typically transcription factors), there is a generally appli-
cable system that allows the timed induction of activity
through fusion of the transcription factor to the ligand bind-
ing domain of a steroid hormone receptor, such as the
glucocorticoid receptor. When expressed in embryos, in the
absence of hormone, such fusions are held in a complexed
inactive form in the cytoplasm. Application of hormone
releases fusion protein from the inactive complex, allowing
it to function as a transcription factor (Kolm and Sive,
1995). This approach to inducibility is, however, not appli-
cable to peptide ligands and their cell surface receptors.
Transgenic based technologies, in mouse and frog, using
regional- and temporal-specific promoters to drive expres-
sion of a gene of interest hold out the potential as a general
method for timed interventions (Kroll and Amaya, 1996;
Lewandoski, 2001). However, the application of such trans-
genic technologies to a given problem is completely depen-
dent on the availability of a suitable regulatory element to
drive the timed expression of a given molecule.
Here, we report the use of a novel drug-inducible growth
factor receptor system in Xenopus laevis embryos. This
system relies on the ability of the synthetic dimerizing agent
AP20187 to drive the dimerization of a mutant FGFR1
receptor and activate its downstream signalling pathway
without the requirement for its normal extracellular li-
gand(s). We show that activation of FGF signalling using
this system recapitulates several previously reported activ-
ities of FGF ligands, including mesoderm induction, repres-
sion of anterior development, and neural posteriorization.
We also show that the competence of neural tissue to ex-
press Hoxa7 and Xcad3 in response to signalling through
FGFR1 is lost by the end of gastrulation.
Our data demonstrate that the system reported here al-
lows the rapid activation of FGF signalling at a desired
point during early amphibian development and will provide
an important new tool for the investigation of growth factor
signalling during early development.
Materials and methods
Embryological methods
Staging of embryos was according to Nieuwkoop and
Faber (1967). Embryos in 33% NAM  5% ficoll were
injected with 5 or 10 nl of the sample into the relevant
blastomeres at the four-cell stage. Animal cap explants were
excised at blastula stage 9 by using tungsten needles. Ex-
plants and whole embryos were treated for the appropriate
time with 1.25 M AP20187 (ARIAD Pharmaceuticals;
www.ariad.com/regulationkits) in 33% NAM  5% ficoll.
mRNA injections
Capped mRNAs were synthesized by using the SP6
Megascript transcription kit (Ambion) and a modified pro-
tocol using a 1:10 ratio of GTP to 5 mM m7G(5)Gppp(5)G
cap. Following synthesis, RNAs were subject to sequential
precipitation with 0.5 M ammonium acetate and 2.5 M LiCl
to remove unincorporated nucleotides.
The Cs2-iFGFR1 plasmid was constructed by cloning
a 2-kb munI fragment from the pSH1/M-FGFR1-FKBPv2-E
plasmid into the EcoRI site of CS2 (Welm et al., 2002).
For transcription, the plasmid was linearized with NotI. The
pSP64T-noggin plasmid was constructed by cloning a PCR
amplified fragment of X. laevis noggin into the BglII site of
pSP64T. For transcription, the plasmid was linearized with
EcoRI. The SP64T-eFGF plasmid was as described in
Isaacs et al. (1994). All plasmids were transcribed with SP6
polymerase.
Western blot analysis
For the analysis of diphospho-ERK levels, 10 animal
caps for each treatment were homogenized in 50 l of
denaturing sample buffer. Aliquots (25 l) were run on 12%
SDS– PAGE gels. Gels were electroblotted onto Hybond-P
membrane (Amersham Biosciences). Membranes were
blocked in PBS-A  0.1% Tween  1% milk powder for
2 h and were probed with a monoclonal anti-diphospho-
ERK antibody (Sigma) at a 1/4000 dilution overnight at
4°C. Membranes were then washed with PBS-A for 45 min
and then reblocked for 1 h with PBSA  0.1% Tween  1%
milk powder  5% horse serum. The secondary antibody
(horse anti-mouse-AP; Vector Labs) was applied at 1/500
dilution for 2 h. Membranes were washed for 45 min, and
colour development was accomplished by using a solution
of NBT and BCIP (Roche).
For the analysis of iFGFR1 protein levels using the
hemagglutinin (HA)-epitope tag, 20 animal caps for each
treatment were homogenized in 50 l of denaturing sample
buffer. Aliquots (45 l) were run on 12% SDS–PAGE gels.
Gels were blotted and blocked as described above. Blots
were probed overnight with an anti-HA-epitope monoclonal
antibody (Covance) at 1/1000 dilution. After washing and
reblocking, the secondary antibody (sheep anti-mouse POD;
Amersham Biosciences) was applied overnight at a di-
lution of 1/2000. After further washing, the signal was
developed by using the ECL Western blotting reagent (Amer-
sham Biosciences) and exposure to Kodak X-OMAT-AR
film.
Whole-mount antibody staining
Antibody staining for diphospho-ERK was carried out as
previously described (Christen and Slack, 1999). The pri-
mary antibody was a monoclonal anti-diphospho-ERK an-
tibody (Sigma) and the secondary was horse anti-mouse-AP
(Vector Labs). Colour development was with BM purple
substrate (Roche). The antibody staining for the HA-
epitope-tagged iFGFR1 protein was carried out by using the
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same protocol. The primary anti-HA-epitope antibody (Co-
vance) was used at a 1/2500 dilution.
RNAase protection analysis
RNA was purified from groups of 3 embryos or groups
of 10 animal caps by extracting tissues in 0.4 ml of 0.1 M
NaCl, 50 mM Tris (pH 8.0), 5 mM EDTA, and 0.5% SDS
followed by phenol/chloroform extraction and ethanol pre-
cipitation. RNase protection analysis was carried out as
described by Isaacs et al. (1992). 32P UTP-labelled antisense
probes were synthesized and hybridized to sample RNA at
50°C overnight and digested with RNase T1 at 700 U/ml for
1 h before running on 6% acrylamide/urea gels. Exposure
time for autoradiographs using Kodak X-omat film was 1–3
days. Autoradiographs were scanned by using a HP flatbed
scanner, and images were processed with Adobe Photoshop.
Hoxa7 probe template was linearized with EcoRI and
transcribed with T7 polymerase (Condie and Harland,
1987). Xbra was linearized with SspI and transcribed with
T7 polymerase (Smith et al., 1991). Xcad3 was linearized
with EcoRI and transcribed with T7 polymerase (Pownall et
al., 1996). NCAM was linearized with EcoRI and tran-
scribed with SP6 polymerase (Balak et al., 1987). The
ubiquitously expressed ornithine decarboxylase (ODC)
mRNA was used as an internal loading control (Isaacs et al.,
1992). ODC was linearized with BglII and transcribed with
T7 polymerase.
Whole-mount in situ hybridization analysis
Wild-type pigmented embryos were cultured to appro-
priate stages, fixed, and processed for in situ hybridization
as described in Isaacs et al., (1998). Expression was visu-
alised by using the BM purple alkaline phosphatase sub-
strate (Roche). DIG-labelled probes used in this study were
as follows. Following colour development, embryos were
fixed and bleached in PBS-A  5% H2O2 for several hours.
Xbra was linearized with ClaI and transcribed with T7
polymerase. Hoxa7 was linearized with BamH1 and tran-
scribed with T7.
Photography
Images of explants and embryos were captured by using
a Research Instruments Spot Junior CCD camera and pro-
cessed with Adobe Photoshop. Westerns blots and chemi-
lumigraphs were scanned by using a HP scanjet scanner.
Results
Activation of FGF signalling in iFGFR1-injected Xenopus
embryos by AP20187
The mutant FGFR1 receptor (iFGFR1) is based on the
murine FGFR1 receptor but lacks its extracellular ligand
binding domain and contains an amino-terminal myristila-
tion sequence, which serves to target the protein to the cell
membrane. Two mutated FKBP12 domains, which act as
Fig. 1. AP20187 rapidly activates signalling through iFGFR1. Fig. 1 is a
Western blot showing levels of diphospho-ERK in animal cap tissue
explants. Uninjected control explants and positive control explants injected
with 5 pg eFGF mRNA were assayed at gastrula stage 10. Explants
injected with 10 pg iFGFR1 mRNA were removed at blastula stage 9 and
treated with 1.25 M AP20187 for 30, 60, and 120 min before assaying.
Fig. 2. Activation of iFGFR1 leads to widespread upregulation of FGF
signalling. Fig. 2 shows whole-mount diphospho-ERK antibody staining of
embryos that were unilaterally injected with 5 pg iFGFR1 mRNA at the
four-cell stage. Embryos are viewed from the animal hemisphere and the
injected side is towards the top. (A, C, and E) Control embryos injected and
harvested at stage 10  30 min, stage 10  60 min, and stage 10  120
min, respectively. (B, D, and F) Injected embryos treated with 1.25 M
AP20187 at stage 10 for 30, 60, and 120 min, respectively.
91M.E. Pownall et al. / Developmental Biology 256 (2003) 89–99
binding sites for the synthetic dimerizing agent AP20187,
are also fused to the carboxy terminus of the FGFR1 intra-
cellular domain. In addition, a hemagglutinin (HA) epitope
tag has been added to the carboxy terminus of the iFGFR1
fusion protein.
It has previously been shown that, in tissue culture cells
and transgenic mice expressing iFGFR1, application of the
AP20187 dimerizing agent leads to activation of the FGF
signalling pathway, as judged by a number of criteria, in-
cluding phosphorylation of ERK and Akt (Welm et al.,
2002). Here, we show that AP20187 rapidly activates the
FGF signalling pathway in X. laevis embryos injected with
iFGFR1 mRNA.
A cDNA coding for iFGFR1 was subcloned into the
Cs2 plasmid. This vector allows the production of syn-
thetic mRNA suitable for injection into frog embryos. The
dimerizing agent AP20187 is not toxic to embryos at con-
centrations up to 10 M is and does not affect normal
development. Initial experiments indicated that injection of
50 pg or more iFGFR1 mRNA resulted in significant num-
bers of abnormal embryos, even in the absence of drug
treatment (data not shown). Presumably, this is due to drug-
independent FGF signalling through iFGFR1 when high
levels of the mutant protein are being expressed. However,
it was found that injecting 5–20 pg iFGFR1 mRNA per
whole embryo produced no significant activation of FGF
signalling in the absence of AP20187, and consequently,
these are the quantities used in experiments reported here to
investigate activation of iFGFR1.
We tested the ability of AP20187 to cause dimerization
of ectopically expressed iFGFR1, and the consequent acti-
vation of the FGF signalling pathway, by analysing for the
presence of activated diphosphorylated ERK (dp-ERK) in
animal caps and whole embryos. Animal caps were ex-
planted at late blastula stage 9 and cultured for at least 60
min in order to allow transient wound-associated-up-regu-
lation of dp-ERK to subside (Christen and Slack, 1999;
LaBonne et al., 1995). Fig. 1 is a Western blot showing that
animal caps injected with 10 pg iFGFR1 mRNA and treated
with AP20187 for 30, 60, and 120 min exhibit levels of
ERK phosphorylation comparable to that seen in positive
control caps that have FGF signalling activated by injection
of 5 pg embryonic FGF (eFGF) mRNA. Caps from em-
bryos injected with 10 pg iFGFR1 mRNA but not treated
with AP20187 exhibit much lower levels of ERK phosphor-
ylation, comparable with that seen in uninjected control
caps.
In order to determine the spatial extent of FGF signalling
Fig. 3. iFGFR1 protein is stable in the tissues of the early embryo. (A) A western blot showing hemagglutinin (HA)-tagged iFGFR1 protein levels in animal
caps tissue explants. Control uninjected animal caps were explanted at blastula stage 9 and cultured until late neurula stage 20. Animal caps were removed
from embryos injected with 10 pg iFGFR1 mRNA at stage 9 and cultured until early gastrula stage 10.5, early neurula stage 13, midneurula stage 17, and
late neurula stage 20. After the culture period, animal caps were then assayed for the presence of HA-tagged protein. The predicted size of iFGFR1 protein
is c. 72 kDa. (B) Whole-mount HA-tag antibody staining of embryos that were injected with 40 pg iFGFR1 mRNA at the four-cell stage. Embryos are viewed
from the animal hemisphere. Embryos were cultured until blastula stage 9. Embryos were then cultured for a further 60 (B, I and II), 120 (B, III and IV),
and 180 min (B, V and VI). Embryos were cultured either in the absence (B, I, III, and V) or presence of 1.25 M AP20187 (B, II, IV, and VI).
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activation possible with this system, we carried out whole-
mount antibody staining directed against dp-ERK in em-
bryos that have been unilaterally injected with 5 pg iFGFR1
mRNA, and subsequently treated with AP20187 at the early
gastrula stage 10 for 30, 60, and 120 min. Fig. 2A, C, and
E shows that, at all time points, injection of iFGFR1 mRNA
alone causes very little ectopic dp-ERK staining. However,
treatment of iFGFR1-injected embryos with 1.25 M
AP20187 results in strong ectopic dp-ERK staining in the
injected half of the embryo within 30 min (Fig. 2B), and
within 60 min, most cells within the injected side show
elevated dp-ERK levels (Fig. 2D). The activation of FGF
signalling persists for at least 120 min in most cells of the
injected side following drug treatment (Fig. 2F). We con-
clude that AP20187 is able to rapidly induce robust and
sustained FGF signalling in most cells overexpressing the
iFGFR1 protein.
The stability of iFGFR1 protein
The persistence of protein translated from injected iF-
GFR1 mRNA was examined. Fig. 3A is a Western blot
probed with an anti-HA-epitope antibody that recognizes
the iFGFR1 protein. It shows that, in animal caps taken
from embryos injected with 10 pg iFGFR1 mRNA, tagged-
protein corresponding to the predicted size of iFGFR1 pro-
tein persists until at least the late neurula stage 20 (approx-
imately 1 day of development at 23°C).
We also examined whether the induction of iFGFR1
dimerization with AP20187 had any significant effect on the
stability of the protein. Fig. 3B shows a number of whole
embryos probed for the presence of HA-epitope-tagged iF-
GFR1. The animal pole region of four-cell-stage embryos
was injected with 40 pg iFGFR1 mRNA and cultured until
midblastula stage 9. Embryos were then cultured for a
further 1, 2, and 3 h either in the absence (Fig. 3B, I, III,
and V, respectively) or presence of 1.25 M AP20187 (Fig.
3B, II, IV, and VI, respectively). Interestingly, at all time
points examined, the staining for iFGFR1-tagged protein is
significantly stronger in embryos treated with AP20187.
This suggests that iFGFR1 present in a dimerized active
signalling complex is actually more stable than the inactive
monomeric protein.
Activation of signalling through iFGFR1 at different time
points
The experiments described above show that injection of
iFGFR1 mRNA and subsequent treatment with AP20187
are able to activate FGF signalling in late blastula and early
gastrula stage embryos. We also show that protein translated
form injected iFGFR1 mRNA persists through gastrula and
neurula stages. However, for this system to be a useful tool
for the analysis of signalling events throughout early devel-
opment, it is important to show that it is possible to activate
signalling at these later time points. Here, we demonstrate
that it is possible to upregulate dp-ERK levels in animal
explants until at least the early neurula stage. Animal cap
explants were taken from iFGFR1-injected embryos at mid-
blastula stage 8 and were then treated with AP20187 for 45
min at late blastula stage 9, midgastrula stage 11.5, and late
gastrula/early neurula stage 13. Fig. 4 shows that, at all three
time points, the addition of AP20187 upregulates the levels
of ERK phosphorylation relative to untreated controls.
Fig. 4. AP20187 can activate signalling through iFGFR1 at the early
neurula stage. Fig. 4 is a Western blot showing levels of diphospho-ERK
in animal cap tissue explants injected with 10 pg iFGFR1 mRNA. Explants
were removed at midblastula stage 8 and treated with 1.25 M AP20187
for 45 min at late-blastula stage 10, midgastrula stage 11.5, and late-
gastrula/early neurula stage 13. Control untreated caps were harvested at
the same time points.
Fig. 5. Activated iFGFR1 induces Xbra expression in animal cap explants.
Fig. 5 shows the results of an RNAase protection assay using probes for the
general mesodermal marker Xbra and the ubiquitous loading control ODC
carried out on embryos and animal cap explants at early gastrula stage 10.5.
At midblastula stage 8, animal cap explants were removed from control
uninjected embryos and embryos injected with 20 pg iFGFR1 mRNA.
After 45 min, control and uninjected caps were treated with 1.25 M
AP20187 and cultured until stage 10.5.
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Activation of mesodermal gene expression in blastula
stage animal caps
It has been known for many years that the activation of
FGF signalling in blastula stage animal cap explants will
activate the expression of mesodermal marker genes and
lead to the differentiation of a number of mesodermal tis-
sue-types (Kessler and Melton, 1994; Kimelman and
Kirschner, 1987; Slack et al., 1987). Here, we demonstrate
that activation of signalling through iFGFR1 during blastula
stages leads to the induction of expression from the general
mesodermal marker Xbra (Smith et al., 1991). Embryos
were injected with 20 pg iFGFR1, and animal caps explants
were then removed at midblastula stage 8. Explants were
cultured for a further 45 min and then treated with AP20187
until early gastrula stage 10.5. Fig. 5 is an RNase protection
analysis showing that uninjected animal caps or uninjected
animal caps treated with AP20187 do not express Xbra. In
addition, animal caps from embryos injected with iFGFR1
but not treated with AP20187, also do not express Xbra.
However, treatment of iFGFR1-injected caps with AP20187
leads to robust Xbra expression. Furthermore, siblings of
these Xbra-expressing caps, when cultured for 3 days at
23°C, will form fluid filled, translucent vesicles (data not
shown) of the sort typically seen when blastula stage animal
caps are treated with FGF (Isaacs et al., 1992; Slack et al.,
1987, 1988). We conclude that activation of signalling
through iFGFR1 is able to accurately mimic the mesoderm-
inducing activity of the FGF family.
The phenotypic effects of ectopic FGF signalling at
different time points
We have used the reported inducible FGF signalling
system to examine the morphological effects of ectopically
activating signalling through iFGFR1 at a number of time
points during early development. Fig. 6B shows that treat-
ment of control embryos with 1.25 M AP20187 has no
significant effect on the normal development in swimming
larva stage 41 embryos. Embryos injected with 10 pg iF-
GFR1 mRNA are also quite normal (Fig. 6C). However,
sibling embryos, injected with 10 pg iFGFR1 mRNA, and
treated with AP20187 at various time points during early
development exhibit a range of striking derangements of
normal development. iFGFR1-injected embryos treated at
midblastula stage 8 fail to gastrulate and lack defined axial
structures (Fig. 6D). A similar phenotype is also produced if
drug treatment is carried out at the early gastrula stage 10
(Fig. 6E). The period of competence for the formation of
this severe phenotype corresponds very well with the re-
ported period of competence of animal hemisphere explants
to respond to mesoderm induction by FGFs (Slack et al.,
1988). This phenotype is very similar to that obtained by
injecting FGF mRNA into embryos (H.V.I., unpublished
Fig. 6. Activation of FGF signalling at different time points has distinct effects on development. Fig. 6 shows the phenotype of embryos at swimming larva
stage 41. (A) Control uninjected embryos. (B) Embryos treated with 1.25 M AP20187. (C) Embryos injected with 10 pg iFGFR1 mRNA. (D–I) Embryos
injected with 10 pg iFGFR1 mRNA and treated with 1.25 M AP20187 from midblastula stage 8, gastrula stages 10, 10.5, 11, 11.5, and 12, respectively.
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data; Thompson and Slack, 1992), and it is likely that, in
part at least, this phenotype arises from the ability of FGFs
to induce ectopic mesoderm in the animal hemisphere tissue
of blastula stage embryos. If, however, AP20187 treatment
is carried out 2 h later, at gastrula stage 10.5, a quite
different phenotype results (Fig. 6F). Embryos complete
gastrulation normally but exhibit greatly reduced axial ex-
tension and a marked reduction in the development of an-
terior structures, such as the cement gland and eyes. The
phenotype of these embryos is similar to that reported for
overexpression of eFGF from a plasmid during gastrula
stages and has been interpreted to result from the posteri-
orizing activity of eFGF on the developing axis (Isaacs et
al., 1994; Pownall et al., 1996). iFGFR1-injected embryos
treated with AP20187 at stage 11 appear relatively normal,
except for a reduction in the size of the eyes and a slight
derangement of the regular pattern of the somites (Fig. 6G).
Activation of signalling through iFGFR1 at mid-to late-
gastrula stage 11.5 and stage 12 has very little obvious
effect on embryo morphology, except for reduction of pig-
mentation in the ventral part of the retina (Fig. 6H and I).
The effects of ectopic FGF signalling during gastrulation
on the expression of Xbra and Hoxa7
We next examined the effects of inducing FGF signalling
during gastrula stages on the expression of Xbra and Hoxa7.
At the end of gastrulation, Xbra is normally expressed in
posterior mesoderm and notochord (Smith et al., 1991).
Hoxa7 is expressed in posterior mesoderm, ectoderm, and
neuroectoderm (Condie et al., 1990; Pownall et al., 1996).
These are two genes that have previously been reported to
be upregulated in Xenopus embryos when eFGF is overex-
pressed from a cytoskeletal actin promoter during gastrula
stages (Pownall et al., 1996). Embryos were injected with
10 pg iFGFR1 mRNA and cultured until early gastrula stage
10.5, when they were treated with AP20187 until late gas-
trula stage 13. Fig. 7A is a lateral view of Xbra expression
in embryos injected with iFGFR1 but not treated with
AP20187 and shows that Xbra expression at this stage is
restricted to the notochord and the most posterior mesoderm
around the closed blastopore. However, Fig. 7B shows that
addition of AP20187 at stage 10.5 leads to a considerable
upregulation of Xbra expression, involving significant
spreading of expression into more anterior regions of the
embryos. This is particularly apparent within the ventral
aspect of the embryo.
Fig. 7C is a lateral view of a stage 13 embryo showing
Hoxa7 expression in embryos injected with iFGFR1
mRNA. Fig. 7D shows that addition of AP20187 to iF-
GFR1-injected embryos at stage 10.5 leads to massive up-
regulation in Hoxa7 expression along the whole of the
anteroposterior axis. The upregulation of known FGF tar-
gets in these experiments confirms that the inducible sig-
nalling system reported here successfully mimics previously
reported activities of the FGF family in Xenopus embryos.
The competence of neuralized ectoderm to FGF signalling
The animal cap explant culture system is a powerful tool
for the analysis of signalling pathways during early devel-
opment. It has provided a simple means of testing the
biological activity of exogenously applied proteins and in-
Fig. 7. Activation FGF signalling during gastrulation results in ectopic
Xbra and Hoxa7 expression. Fig. 7 shows whole-mount in situ hybridiza-
tions carried out on late-gastrula/early neurula stage 13 embryos injected
with 10 pg iFGFR1 mRNA. Embryos are viewed from the side, dorsal to
the top and anterior to the left. Black arrow indicates notochord staining.
White arrow indicates the blastopore. (A, B) The expression of the meso-
dermal marker Xbra. (C, D) The expression of posterior marker Hoxa7.
Embryos in (B) and (D) were treated with 1.25 M AP20187 at gastrula
stage 10.5. The right-hand embryo in (D) is correctly oriented but is
slightly damaged at its anterior end.
Fig. 8. Activation of FGF signalling in neuralized tissue stimulates mor-
phogenetic movements. Animal cap explants from uninjected and injected
embryos were removed at midblastula stage 8 and photographed at late
neurula stage 18. (A) The appearance of control injected caps. (B) The
appearance of animal caps injected with 50 pg mRNA coding for the
neuralizing agent noggin. (C) The appearance of animal caps coinjected
with 10 pg iFGFR1 and 50 pg noggin mRNA. (D–F) Animal caps injected
with 10 pg iFGFR1  50 pg noggin mRNA and treated with 1.25 M
AP20187 at early gastrula stage 10.5, midgastrula stage 11.5, and late
gastrula stage 13, respectively.
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jected mRNAs. Here, we use animal caps, neuralized by the
BMP inhibitor noggin, to investigate the competence of
neural tissue to respond to FGF signalling. We demonstrate
that FGF signalling is able to induce the elongation of
neuralized tissue until the end of gastrula stages. Interest-
ingly, the period of competence of this tissue to express the
posterior markers Hoxa7 and Xcad3 in response to FGF
signalling, is shorter, and this competence is lost before the
end of gastrulation.
Embryos were injected with 50 pg noggin mRNA or
coinjected with 20 pg iFGFR1 and 50 pg noggin mRNA.
Animal cap explants were then removed at blastula stage 9
and then treated with AP20187 at early gastrula stage 10.5,
midgastrula stage 11.5, and late gastrula/early neurula stage
13 and then cultured until mid-neurula stage 18. Fig. 8A
shows that control uninjected animal caps at this stage have
the appearance of rounded-up balls of tissue, as do caps
injected with 50 pg noggin alone (Fig. 8B) and caps injected
with 10 pg iFGFR1  50 pg noggin mRNA but not treated
with AP20187 (Fig. 8C). However, caps injected with iF-
GFR  noggin and treated with AP20187 at all three stages
tested adopt a characteristic elongated “knobbly” appear-
ance (Fig. 8D–F) during neurula stages. Similar elongation
of animal caps treated with FGF and noggin has previously
been reported (Lamb and Harland, 1995).
Fig. 9A is an RNase protection analysis gel confirming
that caps injected with 50 pg noggin mRNA are strongly
neuralized as shown by the high levels of NCAM expres-
sion relative to control uninjected caps. Fig. 9B shows the
expression of the posterior markers Hoxa7 and Xcad3 in
animal caps neuralized with noggin. Caps injected with
noggin mRNA either in the absence or presence of
AP20187 do not express these markers. The coinjection of
iFGFR1  noggin in the absence of AP20187 also does not
lead to detectable expression of the posterior markers. How-
ever, treatment of iFGFR1  noggin-coinjected caps with
drug, at both stage 10.5 and stage 11.5, results in high levels
of posterior marker expression. Interestingly, no expression
of either gene is detectable in coinjected caps treated with
drug at stage 13. These experiments define a window of
competence during gastrula stages when neural tissue is
able to respond to FGF signalling by the activation of
expression from Hoxa7 and Xcad3. Both of these genes
have been reported to be components of an FGF-dependent
pathway which is important for normal posterior develop-
ment (Isaacs et al., 1998; Pownall et al., 1996, 1998).
Fig. 9. Activation of FGF signalling in neuralized tissue induces expression of the posterior markers Hoxa7 and Xcad3. (A) The results of an RNase protection
assay using probes for the neural marker NCAM and the ubiquitous loading control ODC carried out on embryos and animal cap explants at midneurula stage
18. Animal cap explants were removed from control uninjected embryos and embryos injected with 50 pg mRNA coding for the neuralizing agent noggin
at blastula stage 9 and cultured until midneurula stage 18. (B) The results of an RNase protection assay using probes for the posterior markers Hoxa7 and
Xcad3 carried out on embryos and animal cap explants at midneurula stage 18. Animal cap explants were removed from control uninjected embryos and
injected embryos at blastula stage 9. Embryos were injected with 50 pg noggin mRNA or coinjected with 20 pg iFGFR1 and 50 pg noggin mRNA.
noggin-injected caps were treated with 1.25 M AP20187 at stage 10.5. iFGFR1  noggin-injected caps were treated with drug at stages 10.5, 11.5, and
13.
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Discussion
A system for inducing protein dimerization
The naturally occurring product FK506 has a single
binding surface for the cellular protein FKBP12. The
FKBP12 protein can be homodimerized with FK1012,
which consists of two linked molecules of FK506 (Spencer
et al., 1993). A synthetic homodimerizing reagent
(AP20187) has been produced that has a much lower affin-
ity for endogenous FKBP12 and has two binding surfaces
which bind to an engineered form FKBP12 bearing a single
Phe36Val substitution (Fv) (Clackson et al., 1998). If the Fv
domain is fused to another peptide sequence and expressed
in cells, the addition of the hydrophobic, cell-permeable
AP20187 drug will lead to dimerization of the fusion pro-
tein. Given that signalling pathways typically require pro-
tein–protein interactions, the ability to induce dimerization
represents a potentially very useful way to regulate the
activity of cellular processes. Dimerizer-induced signalling
has been shown for several cell surface receptors, including
the T-cell receptor and ErbB receptors (Muthuswamy et al.,
1999, 2001; Spencer et al., 1993).
An inducible FGF signalling system
Another pathway that involves dimerization of signalling
components is the FGF signalling pathway. Signalling by
extracellular FGF ligands requires dimerization of the cell
surface receptor. Binding of ligand at the cell surface results
in dimerization of the receptor to form an active complex.
The receptor components cross-phosphorylate on tyrosine
residues, and this leads to the subsequent activation of the
downstream signalling pathways (Baird and Klagsburn,
1991).
It has recently been reported that AP20187 can activate
signalling through a form of FGFR1 (iFGFR1), which con-
tains two Fv domains fused to the carboxy terminus of
mouse FGFR1 and lacks its extracellular ligand binding
domain (Welm et al., 2002). Here, we report that AP20187
can be used, during the early development of the amphibian
X. laevis, to regulate signalling through iFGFR1. It is an
important finding that AP20187 appears to be readily ab-
sorbed by the embryo and does not interfere with normal
development. In addition, the demonstration that full-length
protein translated from injected iFGFR1 mRNA is still
present in tissue explants at detectable levels until at least
the late neurula stage suggests that this system will be useful
for analysing the role of FGF signalling through all stages of
development up until at least the establishment of the basic
body plan.
Furthermore, our demonstration that it is possible to
induce association and activation of engineered forms of
signalling pathway components with a synthetic dimerizing
agent in early Xenopus embryos suggests that this technol-
ogy should provide an exciting new addition to the tools
available for the study of signalling in early development.
iFGFR1 mimics several activities of the FGF family
Much work has been done in recent years to investigate
the role of FGF signalling in Xenopus development (re-
viewed in Isaacs, 1997; Kessler and Melton, 1994). Homo-
logues of all four mammalian FGF receptors (Golub et al.,
2000), as well as several FGF ligands, have been shown to
be present in Xenopus (Christen and Slack, 1997; Isaacs,
1997; Koga et al., 1999; Yokoyama et al., 2001). In addition
to a function in regulating early mesodermal gene expres-
sion (Amaya et al., 1993; Cornell et al., 1995; Isaacs et al.,
1994; LaBonne and Whitman, 1994; Schulte-Merker and
Smith, 1995), there is ample evidence that FGF signalling
plays a crucial role in patterning the posterior of the embryo
during normal development (Cox Wm and Hemmati-
Brivanlou, 1995; Holowacz and Sokol, 1999; Isaacs et al.,
1994; Lamb and Harland, 1995; Pownall et al., 1996).
In the present study, we show that activation of signal-
ling through iFGFR1 is able to mimic several known activ-
ities of the FGF family in early amphibian development,
including mesoderm induction and neural posteriorization.
Furthermore, activation of ectopic FGF signalling during
blastula and gastrula stage leads to a series of effects on
phenotype that correlate well with these previously reported
activities of FGF.
The nature of competence to respond to FGF signalling
A number of experiments were done to analyse the
effects resulting from activating FGF signalling at various
points during development. The activation of FGF signal-
ling during gastrulation reveals that the period of compe-
tence in which FGF signalling can grossly affect anteropos-
terior pattern only extends to the early/midgastrula stage. In
addition, we show that the period of competence of neural-
ized explants to respond to FGF signalling, as shown by
expression of two posterior homeobox marker genes, only
extends to the midgastrula stage. This period of competence
is slightly longer than that suggested in a previous study,
which used Hoxb9 as marker (Lamb and Harland, 1995).
However, both studies clearly demonstrate that, at some
point during the midgastrula stage, the competence of neu-
ral tissue to express posterior neural markers in response to
FGF is lost. Of course, the period of competence, defined
using tissue explants, might be different from that of neural
tissue in vivo, i.e., within the context of the whole embryo.
Intriguingly, we show that activation of FGF signalling
at the late gastrula stage still causes neuralized explants to
elongate, demonstrating that, at some level, the explants are
still able to respond to FGF signalling. The FGF respon-
siveness of late gastrula tissues is further confirmed by the
observation that induction of signalling through iFGFR1
leads to robust upregulation of ERK phosphorylation at this
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stage. Given the nature of iFGFR1, which activates signal-
ling at the cell surface, it suggests that competence to
respond to FGF signalling is not simply regulated at the
level of the receptor. Our data also suggest that the compe-
tence to respond to an FGF posteriorizing signal might be
regulated at a level downstream of ERK activation. It is also
possible that the posteriorizing activity of FGFs is not me-
diated through ERK but through another route, such as the
PI3 Kinase pathway, which has recently been shown to a
play a role in FGF signalling during Xenopus development
(Carballada et al., 2001). These data serve to underline the
potentially complex nature of competence to respond to a
given signal.
In conclusion, the inducible FGF signalling system de-
scribed here provides a powerful new tool for the investi-
gation of competence to growth factor signalling during
early development. In addition, when combined with the
ability to target injected iFGFR1 mRNA to different tissues,
using the well-defined Xenopus fate map, it should provide
a means for investigating the role of FGF signalling within
different tissues, at different stages of development.
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